1. Home
  2. BNR vs YARW Comparison

BNR vs YARW Comparison

Compare BNR & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$18.73

Market Cap

126.5M

Sector

Health Care

ML Signal

N/A

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$24.33

Market Cap

114.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNR
YARW
Founded
2014
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.5M
114.6M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
BNR
YARW
Price
$18.73
$24.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.4K
★ 136.5K
Earning Date
06-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.79
$23.68
52 Week High
$41.72
$44.28

Technical Indicators

Market Signals
Indicator
BNR
YARW
Relative Strength Index (RSI) 69.89 34.59
Support Level $15.61 $24.00
Resistance Level $18.59 $32.89
Average True Range (ATR) 1.75 2.45
MACD 0.53 -0.12
Stochastic Oscillator 81.45 9.27

Price Performance

Historical Comparison
BNR
YARW

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: